Patent intelligence · US
US 12208167
Coated tablets for pH-dependent release of benzgalantamine
Coated tablets for pH-dependent release of benzgalantamine
Patent details — US 12208167
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jan 28, 2025
- Expiration
- Jan 23, 2045
- Applicant
- ALPHA COGNITION INC.
- Claims
- 25
- CPC classes
- A61K, A61K31/55, A61K9/2846, A61K9/2866
Quick answer
US 12208167 (Coated tablets for pH-dependent release of benzgalantamine) is held by ALPHA COGNITION INC.. Status: granted. Granted Jan 28, 2025. Expires Jan 23, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ALPHA COGNITION INC.
- Grant date
- Expiration
- Claims
- 25
- CPC classes
- A61K, A61K31/55, A61K9/2846, A61K9/2866, A61K9/2886
More from ALPHA COGNITION INC.
Related pharmaceutical patents in our USPTO index.
-
US 12157743
Solid forms of Alpha-1062 gluconate
granted -
US 11795176
Solid forms of Alpha-1062 gluconate
granted -
US 11123351
Pharmaceutical formulation of 3-alpha-ethynyl-3-beta-hydroxyandrostan-17-one oxime
granted -
US 10603326
Pharmaceutical formulation of 3α-ethynyl-3β-hydroxyandrostan-17-one oxime
granted -
US 10351589
3.alpha.-ethynyl, 3.beta.-hydroxy-5.alpha.-pregnan-20-oxime for use in the treatment of CNS disorders
granted -
US 10342804
Steroid compound for use in the treatment of hepatic encephalopathy
granted -
US 10278977
Methods for treating hypersomnolence
granted
Frequently asked questions
What is US patent 12208167?
US 12208167 (Coated tablets for pH-dependent release of benzgalantamine) is held by ALPHA COGNITION INC.. Status: granted. Granted Jan 28, 2025. Expires Jan 23, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12208167?
ALPHA COGNITION INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 12 pharmaceutical patents for this assignee.
When does US 12208167 expire?
Our index shows an expiration date of Jan 23, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.